EVH News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

EV

Mkt Cap

$550.6M

Volume

1.49M

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

Global Value-Based Healthcare Market is Predicted to Cross USD 60 Billion by 2034 | DelveInsightThe value-based healthcare market is experiencing robust growth, projected to reach USD 62 billion by 2034 from USD 16.5 billion in 2025, with a CAGR of ~16%. The shift from fee-for-service to outcome-based payment models is driven by rising healthcare costs, chronic disease burden, and government reimbursement reforms. North America dominates with 72% market share, while Asia-Pacific is expected to record the fastest growth. Key players include Optum, Humana, Evolent Health, Agilon Health, and Privia Health.GlobeNewswire Inc. · Sep 16, 2026

Dr. Abeer AbouYabis Scholarship for Future Doctors Inspires Aspiring Physicians to Tackle Healthcare ChallengesThe Dr. Abeer AbouYabis Scholarship for Future Doctors offers a $1,000 award to undergraduate students pursuing a medical career, encouraging them to envision their impact on the future of healthcare.GlobeNewswire Inc. · Jan 13, 2025

Global Technology Spending On Core Administration in Healthcare Market Size To Worth USD 61.5 Billion By 2033 | CAGR Of 5.86%The global technology spending on core administration in healthcare market is expected to grow from $34.8 billion in 2023 to $61.5 billion by 2033, at a CAGR of 5.86%. The growth is driven by advancements in technologies like edge computing, IoT, and cloud storage, as well as the need for operational efficiency and regulatory compliance.GlobeNewswire Inc. · Aug 12, 2024

Evolent Health (EVH) Reports Q1 Earnings: What Key Metrics Have to SayWhile the top- and bottom-line numbers for Evolent Health (EVH) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.Zacks Investment Research · May 10, 2024

Evolent Health (EVH) Q1 2024 Earnings Call TranscriptEVH earnings call for the period ending March 31, 2024.The Motley Fool · May 10, 2024

Evolent Health (EVH) Q1 Earnings and Revenues Top EstimatesEvolent Health (EVH) delivered earnings and revenue surprises of 61.90% and 6.33%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?Zacks Investment Research · May 9, 2024

In-Depth Examination Of 6 Analyst Recommendations For Evolent HealthEvolent Health (NYSE:EVH) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 3 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 0 0 0 2M Ago 1 3 0 0 0 3M Ago 0 0 0 0 0 Analysts have set 12-month price targets for Evolent Health, revealing an average target of $44.0, a high estimate of $52.00, and a low estimate of $38.00. A 3.3% drop is evident in the current average compared to the previous average price target of $45.50. Investigating Analyst Ratings: An Elaborate Study The perception of Evolent Health by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Daniel Grosslight Citigroup Announces Buy $40.00 - Richard Close Canaccord Genuity Lowers Buy $44.00 $45.00 Anne Samuel JP Morgan Lowers Overweight $52.00 $53.00 Jeff Jones Oppenheimer Announces Outperform $45.00 - Constantine Davides JMP Securities Raises Market Outperform $38.00 $37.00 Richard Close Canaccord Genuity Lowers Buy $45.00 $47.00 Key Insights: Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Evolent ...Full story available on Benzinga.comBenzinga · Apr 22, 2024

Navigating 4 Analyst Ratings For Evolent HealthIn the preceding three months, 4 analysts have released ratings for Evolent Health (NYSE:EVH), presenting a wide array of perspectives from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 3 0 0 0 Last 30D 0 1 0 0 0 1M Ago 1 2 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 0 0 0 0 Analysts have set 12-month price targets for Evolent Health, revealing an average target of $45.0, a high estimate of $52.00, and a low estimate of $38.00. A 1.47% drop is evident in the current average compared to the previous average price target of $45.67. Interpreting Analyst Ratings: A Closer Look The perception of Evolent Health by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Anne Samuel JP Morgan Lowers Overweight $52.00 $53.00 Jeff Jones Oppenheimer Announces Outperform $45.00 - Constantine Davides JMP Securities Raises Market Outperform $38.00 $37.00 Richard Close Canaccord Genuity Lowers Buy $45.00 $47.00 Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Evolent Health. This information provides a snapshot of ...Full story available on Benzinga.comBenzinga · Mar 15, 2024

Does Evolent Health (EVH) Have the Potential to Rally 34.46% as Wall Street Analysts Expect?The average of price targets set by Wall Street analysts indicates a potential upside of 34.5% in Evolent Health (EVH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.Zacks Investment Research · Mar 14, 2024

Wall Street Analysts Predict a 35.7% Upside in Evolent Health (EVH): Here's What You Should KnowThe consensus price target hints at a 35.7% upside potential for Evolent Health (EVH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.Zacks Investment Research · Feb 27, 2024

EV

EVHEvolent Health, Inc Class A Common Stock

EVH

Pay with—

Available Balance0.00

Your PositionYou don't own any EVH yet.

Related Tickers

Earnings